We are international
Donate
TEXT SIZE   


ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA

06.03.13


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related videos
 related articles
ASCO 2013: Dr. Ander...
ASCO 2013: Dr. Jagan...
ASCO 2013: Dr. Kumar...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Weise...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Jagan...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Kumar...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Ghobr...
ASCO 2013: Dr. Lokho...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Raje ...
ASCO 2013: Dr. Pande...
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
ASH 2014: Dr. Shaji ...
ASH 2014: Dr. Shaji ...
Audio Recording of C...
August 2013 Advocate...
Best of ASH 2014 - W...
Breaking News: Pomal...
FDA Recognition of E...
Freelite and Hevylit...
Health Reform and Yo...
Highlights from the ...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
IMF TV
IMWG 2014 Conference...
Infoline
International Myelom...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Living Well With Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute June...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma Minute Sept...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
News Briefing: The L...
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Gains Nation...
The IMF Spearheads N...
The Importance of Cl...
The IMWG Conference ...
The IMWG Conference ...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
ASCO 2013: Dr. Anderson - Overview of the 2013 Annual Meeting of the American Society of Clinical Oncology
ASCO 2013: Dr. Jagannath - Data on New Novel Agents
ASCO 2013: Dr. Kumar - Emerging Trends for Multiple Myeloma Patient Survival
ASCO 2013: Dr. Lonial - Overview of New Novel Agents Presented at ASCO 2013
ASCO 2013: Dr. Richardson - Current Front Line Treatments
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
ASCO 2013: Dr. Palumbo - Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Kumar- Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.
ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM
ASCO 2013: Dr. Lokhorst - Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
ASCO 2013: Dr. Raje - Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
ASH 2014: Dr. Shaji Kumar's Overview
ASH 2014: Dr. Shaji Kumar's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Best of ASH 2014 - What Patients Need to Know
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
Highlights from the 5th Annual IMWG Summit: Part 2
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
IMF TV
IMWG 2014 Conference Series Debate: Making Sense of Treatment
Infoline
International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Living Well With Myeloma:
Understanding the Immune System and Lab Values in Myeloma
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
September 18, 2014
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
One Myeloma Nation
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Gains National Recognition for Myeloma Awareness Month in 2014
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The IMWG Conference Series "Making Sense of Treatment"
Dec. 8, 2014
The IMWG Conference Series "Making Sense of Treatment"
June 11, 2014
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций


You might also be interested in:

Overviews
ASCO 2013: Dr. Anderson - Overview of the 2013 Annual Meeting of the American Society of Clinical Oncology

Ken Anderson, MD
Dana Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Jagannath - Data on New Novel Agents

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA


ASCO 2013: Dr. Kumar - Emerging Trends for Multiple Myeloma Patient Survival

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA


ASCO 2013: Dr. Lonial - Overview of New Novel Agents Presented at ASCO 2013

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - Current Front Line Treatments

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Immunomodulatory Agents
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).

Katja Weisel, MD
University Hospital Tuebingen
Tuebingen, Germany


ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA


ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.

Antonio Palumbio, MD
University Of Turin
Turin, Italy


ASCO 2013: Dr. Palumbo - Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).

Antonio Palumbio, MD
University Of Turin
Turin, Italy


ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA


Proteasome Inhibitors
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA


ASCO 2013: Dr. Kumar- Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA


ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Other Novel Agents
ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA


ASCO 2013: Dr. Lokhorst - Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.

Henk M. Lokhorst, MD
University Medical Center Utrecht
Utrecht, Netherlands
Member, IMF Board of Scientific Advisors


ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Transplant
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.

Antonio Palumbio, MD
University Of Turin
Turin, Italy


Others
ASCO 2013: Dr. Raje - Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.

Noopur Raje, MD
Massachusetts General Hospital
Boston, Massachusetts, USA


ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.

Shivlal Pandey, MD
Mayo Clinic
Rochester, Minnesota, USA